Publications

1. Monitoring the vitamin D package measure

   The Minister of Health, Welfare and Sport (VWS) decided to discontinue the reimbursement of all vitamin D products containing ...

   Report | 01-12-2023

2. Update advice on the lock procedure for the medicinal product atidarsagene autotemcel (Libmeldy®) for the treatment of metachromatic leukodystrophy (MLD)

   The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to renegotiate the price of ...

   Report | 01-12-2023

3. Final report – Case study phase ROR DGM

   The Dutch National Health Care Institute presents its vision on data availability in healthcare, based on 4 completed case ...

   Report | 30-11-2023

4. GVS advice on latanoprost/netarsudil (Roclanda®) for the treatment of glaucoma and ocular hypertension

   The National Health Care Institute has assessed whether latanoprost in combination with netarsudil (Roclanda®) can be included in ...

   Report | 22-11-2023

5. Package advice lock procedure product emicizumab (Hemlibra®) for the treatment of moderate haemophilia A

   The National Health Care Institute has assessed whether emicizumab (Hemlibra®) can be reimbursed from the basic health care ...

   Report | 16-11-2023

6. Orphan drug arrangement givosiran (Givlaari®) for the treatment of acute hepatic porphyria

   Agreements have been made to promote appropriate use of givosiran (Givlaari®) as treatment of acute hepatic porphyria, a rare ...

   Publication | 24-10-2023

7. Conditional inclusion procedure for medicinal products

   This document describes the conditional inclusion procedure for orphan drugs, conditionals and exceptionals.

   Publication | 29-09-2023

8. Advice on a possible candidate for the conditional inclusion of teduglutide (Revestive®)

   The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to designate teduglutide (Revestive®) ...

   Report | 21-09-2023

9. Package advice for the lock procedure medicinal product zanubrutinib (Brukinsa®) for the treatment of chronic lymphocytic leukaemia (CLL)

   The National Health Care Institute has assessed whether the CGRP inhibitor eptinezumab (Vyepti®) can be reimbursed from the basic ...

   Report | 31-08-2023

10. GVS advice fenfluramine (Fintepla®) for the treatment of epileptic seizures in Dravet Syndrome or Lennox-Gastaut Syndrome

    The National Health Care Institute has assessed whether fenfluramine (Fintepla®) can be included in the Medicine Reimbursement ...

    Report | 31-08-2023